"""
Question: 1101

Evidence: We performed tissue culture selection experiments using reverse transcrip- tase inhibitor-resistant viruses containing resistance substitutions at positions K65R, M184I or M184V in the presence of increasing concentrations of RAL, EVG or DTG and monitored changes in integrase sequences by genotyping. The current project was supported by the Canadian Institutes for Health Research (CIHR).

Rationale: The paper explicitly describes performing new tissue culture selection experiments and sequencing analyses to investigate the effects of NRTI resistance mutations on INSTI resistance development. This represents previously unpublished experimental data generated by the authors.

Answer: Yes
"""

"""
Question: 1102

Evidence: Emerging resistance mutations in integrase were detected by extraction of viral RNA from culture fluids using the QIAamp Viral RNA Extraction kit (Qiagen, Toronto, Ontario, Canada), followed by reverse transcription, amplification by PCR and sequencing, as previously described ^\[32\]^ . No additional mutations in reverse transcriptase were observed during our tissue culture selection experiments.

Rationale: The paper describes sequencing HIV sequences from tissue culture experiments, specifically monitoring changes in integrase sequences and confirming no additional mutations in reverse transcriptase.

Answer: Yes
"""

"""
Question: 1103

Evidence: We performed tissue culture selection experiments using reverse transcrip- tase inhibitor-resistant viruses containing resistance substitutions at positions K65R, M184I or M184V in the presence of increasing concentrations of RAL, EVG or DTG and monitored changes in integrase sequences by genotyping. Following activation, CBMCs were infected with K65R -containing, M184I-containing or M184V-containing viral isolates and grown in RPMI1640 medium supplemented with 10% FBS (Life Technologies, Thermo Fisher Scientific, Mississauga, Ontario, Canada) in the presence of increasing RAL, EVG or DTG concentrations, as described previously ^\[11\]^ .

Rationale: The paper explicitly describes performing in vitro passage experiments where viruses were grown in cord blood mononuclear cells with increasing drug concentrations over time, monitoring for emerging resistance mutations.

Answer: Yes
"""

"""
Question: 1104

Evidence: First, we monitored the concentrations of DTG, EVG or RAL at which the wild-type (WT) and various mutated HIV-1 viruses were able to replicate over time ( Fig. 1 ). After 20 weeks of culture, RAL, EVG and DTG concentrations were 0.5 μmol/l, 0.5 μmol/l and 25 nmol/l, respectively.

Rationale: The paper reports the drug concentrations at which different HIV-1 variants could replicate, which represents in vitro antiretroviral susceptibility data showing the relative resistance levels of different viral variants to various INSTIs.

Answer: Yes
"""

"""
Question: 2101

Evidence: NA

Rationale: After thoroughly reviewing the paper content, there is no mention of GenBank accession numbers for any HIV sequences, including laboratory isolates. The paper describes sequencing experiments but does not report deposition of sequences in GenBank.

Answer: No
"""

"""
Question: 2102

Evidence: NA

Rationale: The paper does not mention any GenBank accession numbers for HIV sequences, whether from laboratory isolates or clinical samples. All sequencing appears to have been performed for the specific experiments described without public database deposition.

Answer: No
"""

"""
Question: 2103

Evidence: NA

Rationale: The paper does not report any GenBank accession numbers for HIV sequences. No accession numbers are mentioned in the methods, results, or supplementary materials sections.

Answer: NA
"""

"""
Question: 2202

Evidence: These analyses revealed the absence of resistance mutations in integrase at all times when tissue culture selection experiments were performed with the K65R , M184I or M184V viruses under DTG pressure. In contrast, the WT virus possessed the R263K integrase substitution at weeks 17 and 22 in agreement with previous in-vitro and clinical studies ^\[5,24,33\]^ .

Rationale: The paper reports specific mutations detected in individual sequenced HIV isolates from the tissue culture experiments, as detailed in Table 1, which shows acquired integrase mutations for different viral genotypes under various drug pressures at different time points.

Answer: Yes
"""

"""
Question: 2301

Evidence: NA

Rationale: The paper specifically studies HIV-1, as mentioned in the title and throughout the text ("HIV-1" appears multiple times). There is no mention of HIV-2 or other HIV species being studied.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: NA

Rationale: The paper does not specify the subtypes of the viruses used in the experiments. The viruses were produced from pNL4.3 plasmids, which is a laboratory strain, but no subtype information is provided for the sequenced viruses.

Answer: NA
"""

"""
Question: 2303

Evidence: Emerging resistance mutations in integrase were detected by extraction of viral RNA from culture fluids using the QIAamp Viral RNA Extraction kit (Qiagen, Toronto, Ontario, Canada), followed by reverse transcription, amplification by PCR and sequencing, as previously described ^\[32\]^ . No additional mutations in reverse transcriptase were observed during our tissue culture selection experiments.

Rationale: The paper specifically mentions sequencing the integrase gene to detect resistance mutations and also monitoring for mutations in reverse transcriptase, indicating that both integrase and reverse transcriptase genes were sequenced.

Answer: integrase, reverse transcriptase
"""

"""
Question: 2304

Evidence: No additional mutations in reverse transcriptase were observed during our tissue culture selection experiments. The K65R þ M184I/V combinations of substitutions can be observed in individuals who experience treatment failure with either INSTI-based or non-INSTI-based regimens.

Rationale: The paper reports results of HIV pol sequences, specifically mentioning monitoring of reverse transcriptase mutations (K65R, M184I/V) and confirming no additional mutations in reverse transcriptase during the experiments.

Answer: Yes
"""

"""
Question: 2401

Evidence: NA

Rationale: The paper describes tissue culture experiments using laboratory-derived viruses and does not involve clinical samples from specific geographic regions or countries. All viruses were generated from pNL4.3 plasmids in a laboratory setting.

Answer: NA
"""

"""
Question: 2402

Evidence: NA

Rationale: The paper describes experimental work performed for this study but does not specify the years when the experiments were conducted or when samples were obtained. The paper mentions DTG was approved in 2013 but doesn't provide sample collection dates.

Answer: NA
"""

"""
Question: 2502

Evidence: Emerging resistance mutations in integrase were detected by extraction of viral RNA from culture fluids using the QIAamp Viral RNA Extraction kit (Qiagen, Toronto, Ontario, Canada), followed by reverse transcription, amplification by PCR and sequencing, as previously described ^\[32\]^ .

Rationale: The description of sequencing methodology involving PCR amplification and sequencing without mention of next-generation sequencing technologies suggests standard Sanger sequencing was used, which is typical for such resistance genotyping studies.

Answer: Yes
"""

"""
Question: 2503

Evidence: NA

Rationale: The paper describes traditional sequencing methods involving PCR amplification and sequencing but does not mention the use of next-generation sequencing (NGS) technologies. The methods section suggests standard population sequencing approaches.

Answer: No
"""

"""
Question: 2504

Evidence: NA

Rationale: The paper does not mention that samples were cloned prior to sequencing. The sequencing appears to have been performed on bulk PCR products from viral populations without cloning.

Answer: No
"""

"""
Question: 2505

Evidence: NA

Rationale: The paper does not mention single genome sequencing being performed. The sequencing methodology described suggests population sequencing of bulk PCR products.

Answer: No
"""

"""
Question: 2506

Evidence: Viruses were produced from previously described pNL4.3 plasmids that were generated by site-directed mutagenesis ^\[30,31\]^ .

Rationale: The paper describes using site-directed mutagenesis to create the viral variants used in the experiments, which involves molecular cloning techniques to introduce specific mutations into the pNL4.3 plasmid.

Answer: Yes
"""

"""
Question: 2601

Evidence: NA

Rationale: The paper describes tissue culture experiments using viruses grown in cord blood mononuclear cells, not clinical plasma samples from infected individuals. All sequencing was performed on viruses from culture fluids, not directly from patient plasma.

Answer: No
"""

"""
Question: 2602

Evidence: NA

Rationale: The paper describes experiments using cord blood mononuclear cells (CBMCs) for viral propagation, but these are not patient PBMC samples. The sequencing was performed on viruses from culture fluids, not from patient PBMC DNA.

Answer: No
"""

"""
Question: 2603

Evidence: NA

Rationale: The paper does not report any plasma virus sequencing from clinical samples. All sequencing was performed on viruses from tissue culture experiments.

Answer: 0
"""

"""
Question: 2604

Evidence: NA

Rationale: The paper does not report any PBMC virus sequencing from clinical samples. The cord blood mononuclear cells were used for viral propagation in culture, not as source material for sequencing patient-derived viruses.

Answer: 0
"""

"""
Question: 2605

Evidence: Following activation, CBMCs were infected with K65R -containing, M184I-containing or M184V-containing viral isolates and grown in RPMI1640 medium supplemented with 10% FBS. HIV-1 replication was measured through weekly quantification of reverse transcriptase activity in culture fluids in the presence and absence of drug.

Rationale: The sequences were obtained from viruses actively replicating in tissue culture, as evidenced by weekly monitoring of reverse transcriptase activity and viral replication in the presence of drugs.

Answer: Yes
"""

"""
Question: 2606

Evidence: NA

Rationale: The sequences were obtained from viral RNA in culture fluids, not from proviral DNA in cellular reservoirs. The paper does not mention sequencing of integrated proviral DNA.

Answer: No
"""

"""
Question: 2701

Evidence: Primary human cord blood mononuclear cells (CBMCs) isolated from cord blood obtained through the Department of Obstetrics, Jewish General Hospital, Montréal, Canada.

Rationale: The paper used cord blood mononuclear cells from newborns/infants as the cellular substrate for viral propagation experiments, indicating samples were obtained from infants/children.

Answer: Yes
"""

"""
Question: 2702

Evidence: NA

Rationale: The paper describes laboratory experiments using tissue culture systems and does not involve human subjects participating in clinical trials. All work was conducted in vitro.

Answer: No
"""

"""
Question: 2703

Evidence: NA

Rationale: The paper does not involve any human subjects in clinical trials. The research consists entirely of in vitro experiments using laboratory-generated viruses and cord blood cells.

Answer: No
"""

"""
Question: 3101

Evidence: NA

Rationale: The paper describes in vitro experiments using laboratory-generated viruses and does not involve human subjects from whom samples were obtained for HIV sequencing.

Answer: 0
"""

"""
Question: 3102

Evidence: NA

Rationale: The paper does not involve human subjects undergoing HIV sequencing. All sequencing was performed on viruses from tissue culture experiments.

Answer: No
"""

"""
Question: 4101

Evidence: NA

Rationale: The paper describes in vitro experiments using laboratory-generated viruses and does not involve clinical samples from ART-naive individuals.

Answer: No
"""

"""
Question: 4102

Evidence: NA

Rationale: The paper describes in vitro experiments using laboratory-generated viruses with specific resistance mutations, but does not involve clinical samples from ART-experienced individuals.

Answer: No
"""

"""
Question: 4103

Evidence: NA

Rationale: The paper does not report HIV sequences from any individuals, whether ART-naive or ART-experienced. All sequences are from laboratory viruses used in tissue culture experiments.

Answer: No
"""

"""
Question: 4104

Evidence: NA

Rationale: The paper does not involve clinical samples from ART-naive individuals. All experiments used laboratory-generated viruses.

Answer: 0
"""

"""
Question: 4105

Evidence: NA

Rationale: The paper does not involve human subjects with ART histories, as it describes in vitro experiments using laboratory-generated viruses.

Answer: No
"""

"""
Question: 4201

Evidence: NA

Rationale: The paper describes laboratory selection experiments and does not report epidemiological data on the prevalence of transmitted HIV drug resistance in any population.

Answer: No
"""

"""
Question: 4202

Evidence: NA

Rationale: The paper describes laboratory selection experiments and does not report data on the prevalence of pretreatment HIV drug resistance in clinical populations.

Answer: No
"""

"""
Question: 4301

Evidence: NA

Rationale: The paper describes in vitro experiments and does not involve human subjects who received drug classes. The drugs tested (RAL, EVG, DTG, 3TC, TFV) were used in tissue culture, not administered to individuals.

Answer: NA
"""

"""
Question: 4302

Evidence: NA

Rationale: The paper describes in vitro experiments and does not involve human subjects who received integrase inhibitors. The INSTIs were tested in tissue culture systems.

Answer: No
"""

"""
Question: 4303

Evidence: NA

Rationale: The paper describes in vitro experiments and does not involve human subjects who received protease inhibitors. No protease inhibitors are mentioned in the study.

Answer: No
"""

"""
Question: 4304

Evidence: NA

Rationale: The paper does not involve human subjects receiving ART regimens. All drug testing was performed in tissue culture systems.

Answer: NA
"""

"""
Question: 4305

Evidence: NA

Rationale: The paper does not involve human subjects, so the question of whether individuals were INSTI-naive is not applicable. The viruses used were laboratory-generated, not from patients with treatment histories.

Answer: NA
"""

"""
Question: 4403

Evidence: NA

Rationale: The paper does not involve human subjects receiving ART regimens, so information about multiple ART regimens is not available.

Answer: 0
"""

"""
Question: 4404

Evidence: NA

Rationale: The paper does not involve human subjects receiving ART regimens, so information about multiple ART regimens is not available.

Answer: 0
"""

"""
Question: 4405

Evidence: NA

Rationale: The paper does not involve human subjects receiving ART regimens, so this question is not applicable.

Answer: NA
"""

"""
Question: 4406

Evidence: NA

Rationale: The paper does not involve human subjects receiving ART regimens, so this question is not applicable.

Answer: NA
"""

"""
Question: 4501

Evidence: NA

Rationale: The paper does not involve human subjects receiving dolutegravir. DTG was tested in tissue culture experiments but not administered to individuals.

Answer: 0
"""

"""
Question: 4502

Evidence: NA

Rationale: The paper does not involve human subjects receiving darunavir. Darunavir is not mentioned in the study.

Answer: 0
"""

"""
Question: 5101

Evidence: NA

Rationale: The paper does not involve human subjects being tested for drug resistance mutations. All resistance mutation analysis was performed on laboratory viruses from tissue culture experiments.

Answer: 0
"""

"""
Question: 5102

Evidence: NA

Rationale: The paper does not involve human subjects being tested for INSTI-resistance mutations. All resistance mutation analysis was performed on laboratory viruses from tissue culture experiments.

Answer: 0
"""

"""
Question: 5103

Evidence: NA

Rationale: The paper does not involve human subjects being tested for TDF-resistance mutations. All resistance mutation analysis was performed on laboratory viruses from tissue culture experiments.

Answer: 0
"""

"""
Question: 5104

Evidence: These analyses revealed the absence of resistance mutations in integrase at all times when tissue culture selection experiments were performed with the K65R , M184I or M184V viruses under DTG pressure. In contrast, the WT virus possessed the R263K integrase substitution at weeks 17 and 22. The T66I substitution in integrase was detected with both RAL and EVG when the M184I virus was propagated for 22 and 12 weeks, respectively.

Rationale: The paper reports specific INSTI-resistance mutations that developed during tissue culture experiments, including R263K (for DTG with WT virus), T66I (for EVG and RAL with various mutants), N155H, Y143H, and others as detailed in Table 1.

Answer: R263K, T66I, N155H, Y143H, T97A, E92Q, S147G, S153F, Q148K, G163R, D232N, A128T
"""

"""
Question: 6101

Evidence: HIV-1 replication was measured through weekly quantification of reverse transcriptase activity in culture fluids in the presence and absence of drug. Drug concentrations were raised by 2.5-fold when levels of replication in the presence of antiviral compound were similar to those in the absence of drug.

Rationale: The paper describes a phenotypic susceptibility testing method where viral replication is monitored by measuring reverse transcriptase activity in culture fluids under increasing drug concentrations, which represents a tissue culture-based phenotypic assay.

Answer: Tissue culture-based viral replication assay measuring reverse transcriptase activity
"""

"""
Question: 6102

Evidence: The highest dose of DTG attained in our tissue culture experiments was 25nmol/l (Fig. 1), a concentration that is below the reported protein-adjusted IC90 (64 ng/ml, 152 nM) for this drug [43,44]. In contrast, EVG concentrations could be raised to more than 250 nmol/l when infections were initiated with any of the WT, M184Vor K65R viruses (Fig. 1), a level that is above its reported protein-adjusted IC95 (45 ng/ml, approxi- mately 100.5 nmol/l) [43 – 45].

Rationale: The paper references IC90 and IC95 values from literature for DTG and EVG, and reports the maximum drug concentrations achieved in their experiments relative to these IC values.

Answer: Yes
"""

"""
Question: 6103

Evidence: NA

Rationale: The paper reports actual drug concentrations achieved in experiments and references literature IC values, but does not report IC50 fold change values for the tested viruses compared to wild-type.

Answer: No
"""

"""
Question: 6104

Evidence: Following activation, CBMCs were infected with K65R -containing, M184I-containing or M184V-containing viral isolates and grown in RPMI1640 medium supplemented with 10% FBS (Life Technologies, Thermo Fisher Scientific, Mississauga, Ontario, Canada) in the presence of increasing RAL, EVG or DTG concentrations. HIV-1 replication was measured through weekly quantification of reverse transcriptase activity in culture fluids in the presence and absence of drug.

Rationale: The paper used a tissue culture-based phenotypic susceptibility assay in cord blood mononuclear cells, monitoring viral replication through reverse transcriptase activity measurements under increasing drug pressure.

Answer: Tissue culture-based assay in cord blood mononuclear cells measuring reverse transcriptase activity
"""

"""
Question: 6105

Evidence: Altogether, the data suggest that DTG has a higher barrier to development of resistance than any of 3TC, TFV, RAL and EVG because of the inability of NRTI-resistant viruses to acquire resistance mutations against DTG (current study), the decreased ability of DTGresistant viruses to become resistant against reverse transcriptase inhibitors [41] and the decreased viral replication capacity of viruses containing both the R263K and either K65R or M184I/V mutations [30,31].

Rationale: The paper discusses replication capacity in the context of viral fitness, specifically mentioning that viruses with R263K combined with K65R or M184I/V mutations have decreased replication capacity, and references previous studies on this topic.

Answer: Yes
"""

"""
Question: 6106

Evidence: We performed tissue culture selection experiments using reverse transcrip- tase inhibitor-resistant viruses containing resistance substitutions at positions K65R, M184I or M184V in the presence of increasing concentrations of RAL, EVG or DTG and monitored changes in integrase sequences by genotyping. 3TC and TFV were obtained through the National Institutes of Health (NIH) AIDS Reagent Program.

Rationale: The paper tested several drugs in phenotypic susceptibility assays, including the integrase strand transfer inhibitors RAL (raltegravir), EVG (elvitegravir), and DTG (dolutegravir), and also mentions 3TC (lamivudine) and TFV (tenofovir) being used in the experiments.

Answer: RAL (raltegravir), EVG (elvitegravir), DTG (dolutegravir), 3TC (lamivudine), TFV (tenofovir)
"""

"""
Question: 7101

Evidence: Viruses were produced from previously described pNL4.3 plasmids that were generated by site-directed mutagenesis ^\[30,31\]^ . We performed tissue culture selection experiments using reverse transcrip- tase inhibitor-resistant viruses containing resistance substitutions at positions K65R, M184I or M184V.

Rationale: The paper explicitly states that the viral isolates used in the experiments were generated through site-directed mutagenesis of pNL4.3 plasmids to introduce specific resistance mutations (K65R, M184I, M184V).

Answer: Yes
"""

"""
Question: 7102

Evidence: We performed tissue culture selection experiments using reverse transcrip- tase inhibitor-resistant viruses containing resistance substitutions at positions K65R, M184I or M184V in the presence of increasing concentrations of RAL, EVG or DTG and monitored changes in integrase sequences by genotyping.

Rationale: The paper describes conducting in vitro passage experiments where viruses were grown in tissue culture under increasing drug pressure, and these experiments resulted in the selection of new resistance mutations in integrase as documented in Table 1.

Answer: Yes
"""